Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

ADMA Biologics Inc. ($ADMA) stock shot up as the company announced it is well on its way to get an acquired biologics manufacturing facility back on track. The company CEO Adam Grossman wrote a letter to shareholders stating that Boca Raton, Florida site is expected to be “inspection ready” in about six months. The facility is likely to be used for producing BIVIGAM and Nabi-HB (Hepatitis B Immune Globulin, Human). ADMA also expects to refile the Biologics License Application (BLA) for lead candidate RI-002 by mid-2018.
The company stock jumped over 12 percent in its previous trading session, trimming its Year to Date losses to 20 percent.

Spectranetics Corp ($SPNC) stock reacted positively to the news of Philips acquisition. The company has agreed to be bought by Philips for $2.16 billion including debt. Spectranetics is a manufacturer of devices to treat heart disease. Philips is looking to expand its  image-guided therapy business with this acquisition. Spectranetics uses various techniques such as lasers and tiny drug-covered balloons to clean clogged veins and arteries. The deal has valued Spectranetics stock at $38.50 per share, a 27 percent premium to their closing price on June 27.
The company stock jumped over 26 percent in the pre-market session.

 

Histogenics ($HSGX) announced that it has hit the enrollment target of 245 subjects in a Phase 3 clinical trial assessing  NeoCart for the treatment of cartilage defects in the knee. The company expects the top-line one year data to be available in the third quarter of 2018.

DS Healthcare Group ($DSKX) reported settling its breach-of-contract litigation with former merger partner Photomedex.  The company cited the preference to eliminate uncertainties and further expenses as the reasons behind the settlement.

Agile Therapeutics ($AGRX) announced the re-submission of its New Drug Application  to the FDA seeking approval of lead product candidate Twirla. The company had received a Complete Response Letter in February 2013 citing the need for an additional clinical trial and additional information on the manufacturing process.

KaloBios Pharmaceuticals ($KBIO) announced receiving the FDA approval for its Investigational New Drug (IND) for benznidazole for the treatment of Chagas disease. The company said that it intends to file its NDA in the first quarter of 2018 and may use the abbreviated 505(b)(2) pathway allowing the inclusion of data generated by others.

 

Chembio Diagnostics ($CEMI) announced inking an “at the market” deal with Cantor Fitzgerald for selling up to $21.2 million of common stock. The company plans to use the net proceeds for meeting general corporate expenses.

Henry Schein ($HSIC) reported that it will record a $0.04 charge to EPS for this quarter. The charge is on account of its settlement related to a lawsuit filed by SourceOne Dental. The company was sued, along with Patterson and Benco Dental Supply over the accusation of illegal boycotts and stifling competition.

Brokerage
Action
Company
Rating
Price Target
Impact on Share Price
Maxim Group
Reiterates
ADMA Biologics (ADMA)
Buy
$13.00
N/A
Citigroup
Initiates
Aetna (AET)
Buy -> Focus List

Low
Credit Suisse Group
Downgrades
Alder BioPharmaceuticals (ALDR)
Outperform -> Neutral

Low
Deutsche Bank AG
Upgrades
Bio-Rad Laboratories (BIO)
Hold -> Buy

Low
Wedbush
Reiterates
Bioverativ (BIVV)
Market Perform

Low
Argus
Initiates
HCA Holdings (HCA)
Buy

N/A

Gainers (% price change)
Last Trade
Change
Mkt Cap
OraSure Tech., Inc.
OSUR
17.30
+1.58 (10.05%)
1.01B
AVEO Pharmaceuticals, Inc
AVEO
2.09
+0.14 (7.18%)
359.83M
NxStage Medical, Inc.
NXTM
24.55
+1.09 (4.65%)
1.62B
Atrion Corporation
ATRI
612.60
+15.85 (2.66%)
1.15B
BioScrip Inc
BIOS
2.84
+0.07 (2.53%)
355.13M
Losers (% price change)

Curis, Inc.
CRIS
2.00
-0.22 (-9.91%)
303.98M
Omeros Corporation
OMER
22.47
-2.32 (-9.36%)
951.99M
Seattle Genetics, Inc.
SGEN
51.39
-5.16 (-9.12%)
6.72B
Progenics Pharmaceuticals
PGNX
6.90
-0.55 (-7.38%)
480.68M
Sangamo Therapeutics Inc
SGMO
8.70
-0.65 (-6.95%)
715.07M
Most Actives (dollar volume)

Johnson & Johnson
JNJ
135.01
-1.33 (-0.98%)
363.45B
Gilead Sciences, Inc.
GILD
70.65
-0.59 (-0.83%)
93.26B
Regeneron Pharmaceuticals
REGN
502.12
-13.79 (-2.67%)
53.22B
Valeant Pharmaceuticals
VRX
16.65
-0.43 (-2.52%)
6.14B
Celgene Corporation
CELG
130.85
-3.00 (-2.24%)
101.82B